Be Biopharma is looking to hire highly motivated, experienced, and innovative thinkers to join our growing team of passionate researchers to leverage B cells as a novel class of cellular medicine. This is an exciting opportunity to be part of a foundational team and help build Be Bio!
- Help to establish protocols around differentiation of primary immune cells, including extensive tissue culture work (maintenance, expansion, and banking)
- Handling and analyzing workflows pertaining to cellular differentiation and profiling with downstream qRT-PCR, protein quantification, and other molecular readouts
- Cloning of constructs to support cellular engineering efforts
- Detailed record-keeping and protocol refinement as related to molecular and cellular assays
- Facilitate efficient transfer of assays to CRO partners where applicable
- Bachelor’s and 2+ years, or Master’s and 1+ years experience in a biopharmaceutical or biotechnology company
- Experience in molecular biology techniques and cell culture (primary immune cells, B cells preferred)
- Proven ability to establish and troubleshoot molecular biology assays
- Excellent written and communication skills, ability to present scientific data
- Ability to work collaboratively in a team setting and independently as needed
- Clear demonstration of reproducible science with an attention to detail
Be Biopharma is pioneering a new class of medicines, unleashing the power of B cells to create the new field of Engineered B Cell Medicines. B cells are the body’s protein producing factories, most widely known for making antibodies. Our leading B cell therapy platform, developed by the top scientific KOLs in the field and with strong IP protection, harnesses this capability to engineer B cells to produce any protein with potential therapeutic application. This creates a unique opportunity to rapidly design and develop a broad portfolio of disease changing products (our platform affords ready swapping in new genes for different disease indications) and to significantly scale the company to realize substantial value in a short period of time.
Importantly, and in contrast to other cell therapy modalities, Engineered B Cells engraft naturally (and thus are not expected to require preconditioning chemotherapy). They are also “naturally allogeneic”, and we expect most or all of our portfolio to be “off-the-shelf” medicines. We have a rich pipeline of initial medicines under development in Oncology and Severe Genetic Disease, and we will subsequently expand to other important indications (e.g. Infectious Disease, Autoimmune Disease, etc).
Our Cambridge-based team is led by highly experienced, mission-driven executives all of whom are experienced cell therapy veterans who played key roles in developing several of today’s most impactful marketed gene and cell therapies. The team is rapidly expanding, with 20 employees joining in the first half of 2021. We are making major strides in our proof-of-concept studies for our lead programs in Oncology and Rare Disease, which are on track for near-term clinical development. Be Biopharma was founded in 2020 with a 52M Series A financing round supported by a syndicate of leading biotech investors (Longwood Fund, Atlas, RA Capital, Alta).
The beating heart of Be Bio is our People and together we are building a culture driven by purpose, passion, and that’s full of character. We are “all-in” as we align ourselves with patients who need our medicines, and we embrace the highest standards of transparency, excellence, candor, collaboration, and team-based science with a shared ownership of company milestones and successes.
Our commitment to our team members is to deliver a compelling, dynamic work experience that enables them to continually stretch, grow, and learn, that enriches their lives, that fosters a sense of belonging and community, and that goes above and beyond to support them in big, meaningful ways in both their personal and professional lives. Be Bio is a team that works hard, plays hard, and supports each other on our shared journey to get transformative medicines to patients who need them.